# SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma

> **NCT00006013** · PHASE2 · COMPLETED · sponsor: **Fox Chase Cancer Center** · enrollment: 21 (actual)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** semaxanib

## Key facts

- **NCT ID:** NCT00006013
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** 2003-01
- **Final completion:** 2003-01
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2013-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006013, "SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00006013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*